Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

37
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
37
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

14
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
14
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

11
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
11
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

15
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
15
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Vaccinations01:51

Vaccinations

44.6K
Overview
44.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced electrochemical performance of eco-friendly Cr-doped ZnO/RGO nanocomposites for pioneering supercapacitor applications.

Frontiers in chemistry·2026
Same author

Latent fingerprint development ability of spinel copper aluminate (CuAl<sub>2</sub>O<sub>4</sub>) nanoparticles.

Frontiers in chemistry·2026
Same author

The recent progress in the catalytic conversion of nitroarene into amino arene catalyzed by heterogeneous metal based nano catalyst.

Frontiers in chemistry·2026
Same author

Hughes-Stovin syndrome (HSS) preliminary diagnostic criteria: a paradigm shift in managing pulmonary vasculitis in HSS and Behçet's disease (BD). On behalf of the HSS International Study Group (HSSISG) : Reply on Tahir Saygın Öğüt and Veli Yazısız "Comments on the proposed diagnostic criteria for Hughes-Stovin syndrome: the role of Behçet syndrome" (CLRH-D-26-01350).

Clinical rheumatology·2026
Same author

Seronegative polymyalgia rheumatica: an update.

Reumatologia·2026
Same author

In vitro and in vivo investigations of antibacterial B-TCP/polymer composite enhanced with strontium for bone grafting and photocatalytic applications.

Cytotechnology·2026

Related Experiment Video

Updated: Jul 12, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

144

New-Onset Rheumatic Immune-Mediated Inflammatory Diseases Following SARS-CoV-2 Vaccinations until May 2023: A

Arvind Nune1, Victor Durkowski2, S Sujitha Pillay3

  • 1Department of Rheumatology, Southport and Ormskirk NHS Trust, Southport PR8 6PN, UK.

Vaccines
|October 28, 2023
PubMed
Summary

COVID-19 vaccines may trigger new rheumatic immune-mediated inflammatory diseases (R-IMIDs) in adults. This systematic review analyzed 271 cases, finding vasculitis and connective tissue diseases were most common, with most patients improving after treatment.

Keywords:
COVID-19 vaccinesadverse events following immunizationconnective tissue diseasesimmune-mediated inflammatory diseaseinflammatory arthritisrheumatic diseasevasculitis

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

476
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.1K

Related Experiment Videos

Last Updated: Jul 12, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

144
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

476
Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis
26:48

Induction and Clinical Scoring of Chronic-Relapsing Experimental Autoimmune Encephalomyelitis

Published on: July 4, 2007

18.1K

Area of Science:

  • Rheumatology
  • Immunology
  • Vaccinology

Background:

  • New-onset rheumatic immune-mediated inflammatory diseases (R-IMIDs) following COVID-19 vaccination require comprehensive investigation.
  • Existing literature lacks a systematic review on R-IMIDs post-SARS-CoV-2 vaccination.

Purpose of the Study:

  • To investigate the demographics, management, and prognosis of new R-IMIDs in adults after COVID-19 vaccination.
  • To systematically review the literature on R-IMIDs following SARS-CoV-2 vaccination.

Main Methods:

  • Systematic literature search of Medline, Embase, Google Scholar, LitCovid, and Cochrane.
  • Inclusion of English-language studies reporting new-onset R-IMID in adults post-COVID-19 vaccination.
  • Analysis of 271 cases reported globally between January 2021 and May 2023.

Main Results:

  • The average patient age was 56, with a female predominance (62.5%).
  • Pfizer BioNTech vaccine was most frequently implicated (56.5%), with nearly 50% of cases occurring after the second dose.
  • Vasculitis (31.7%) and connective tissue disease (24.3%) were the most common R-IMIDs, with a mean onset of 11 days post-vaccination.
  • Most patients received corticosteroids (81.2%) and/or DMARDs (42%).
  • Complete remission was achieved in 27.7% and improvement in 50.6% of cases; two deaths due to myositis were reported.

Conclusions:

  • SARS-CoV-2 vaccines may be a trigger for new-onset R-IMIDs.
  • While most patients showed improvement with treatment, further epidemiological studies are needed to understand the long-term implications.